Ignite Creation Date:
2025-12-24 @ 6:51 PM
Ignite Modification Date:
2025-12-25 @ 4:23 PM
Study NCT ID:
NCT04796857
Status:
UNKNOWN
Last Update Posted:
2021-03-15
First Post:
2021-03-10
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL
Sponsor:
Huiqiang Huang
Organization:
Study Overview
Official Title:
Tislelizumab in Combination With Lenalidomide in in Patients With Relapsed or Refractory Elderly Patients With Non-GCB Diffuse Large B Cell Lymphoma: a Prospective Phase Ib/II, Multicentre, Open-label, Single-arm Trial
Status:
UNKNOWN
Status Verified Date:
2021-03
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Aim of this study will evaluate the efficacy and safety of tislelizumab in combination with lenalidomide in in patients with relapsed or refractory Elderly Patients with non-GCB Diffuse Large B Cell Lymphoma
Detailed Description:
Elderly patients with relapsed /refractory non-GCB diffuse large B cell lymphoma usually have a bad prognosis. These patients cannot be treated successfully or tolerated the conventional chemotherapy. Lenalidomide has a unique therapeutic effect in Non-GCB DLBCL. Some studies have shown that the combination of lenalidomide and PD-1 antibody shows a synergistic effect in the exploration of DLBCL, and the patients are well tolerated.The investigators will evaluate the efficacy and safety of tislelizumab in combination with lenalidomide in the elderly patients with relapsed refractory non-GCB DLBCL failed from second line chemotherapy.
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: